SCHEMBL4757474

SCHEMBL4757474

O=C(O)N1CCC(O)CC1C1CCCN(c2ccc(F)cc2F)C1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
HTT P42858 1/20 0.39
ACACB O00763 1/20 0.36
CHRM4 P08173 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
F10 P00742 1/20 0.35
GRM5 P41594 1/20 0.34
NOTUM Q6P988 1/20 0.34
USP30 Q70CQ3 2/20 0.34
ALDH1A1 P00352 1/20 0.34
HSD11B1 P28845 1/20 0.33
HCRTR1 O43613 1/20 0.33
HCRTR2 O43614 1/20 0.33
MAPT P10636 1/20 0.33
DPP4 P27487 1/20 0.33
DPP9 Q86TI2 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5661256 0.90 CCR1 (0.41) KDM4EHTTACACBSMN1; SMN2F10
SCHEMBL4759950 0.87 USP30 (0.45) CHRM4SMN1; SMN2USP30ALDH1A1DPP4
SCHEMBL5659856 0.87 HTT (0.39) KDM4EHTTACACBCHRM4SMN1; SMN2
SCHEMBL5662801 0.77 USP30 (0.39) SMN1; SMN2USP30ALDH1A1DPP4
SCHEMBL4823139 0.76 CCR1 (0.46) ACACBSMN1; SMN2ALDH1A1HCRTR1HCRTR2
SCHEMBL4706042 0.75 HTT (0.49) KDM4EHTTACACBSMN1; SMN2F10
SCHEMBL4706540 0.74 KDM4E (0.39) KDM4EHTTACACBCHRM4SMN1; SMN2
SCHEMBL5661919 0.71 MEN1 (0.53) KDM4ESMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL4757473 0.70 ACACB (0.44) KDM4EHTTACACBSMN1; SMN2GRM5
SCHEMBL22581702 0.69 GAA (0.44) HTTACACBSMN1; SMN2GRM5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP claimed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US claimed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO claimed
EP-1979318-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2008-10-15 EP disclosed
US-20070197530-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-23 US disclosed
WO-2007089683-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197530-A1 Amido compounds and their use as pharmaceuticals HSD11B1, HSD17B11, CYP11B1 KDM4E 2999/4885HTT 2385/4885ACACB 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.